Eisai to enable Alzheimer's drug Leqembi to be injected at home

TOKYO -- Japanese pharmaceutical company Eisai plans to further develop lecanemab, the Alzheimer's disease drug that has been approved in the U.S. for intravenous administration, so that it can be easily injected subcutaneously by patients or caregivers at home, Nikkei has learned.